A web management system for patients who live with Sickle Cell disorder
Research type
Research Study
Full title
Testing the usability and effectiveness of a web base system for therapeutic monitoring for clinicians and patients with sickle cell disorder
IRAS ID
187429
Contact name
Mohammed khalaf
Contact email
Sponsor organisation
Liverpool john moors university
Duration of Study in the UK
1 years, 5 months, 17 days
Research summary
The research study here in involves testing a new remote patient monitoring system that comprises a web-based solution for people with sickle cell disease. The system requires direct interaction from the patient when they experience symptoms or when they take their prescribed medication. It enables patients to live more safely at home and maintain their health condition for as long as possible.\n\nOur novel technology assesses an individual’s personal daily activities by monitoring their symptoms and time\ndosage taking at home. This is achieved by processing data collected from the web-based system, which captures detailed habits of an individual’s interactions with the web interface. Subsequently, all information will be accessed by the clinical team using a variety of statistical methods. The technology can provide further information about patient well-being, by analysing the responses which are collected from the web-based system. For example, a sickle cell disease patient usually suffers from decreased heartbeat and breathing difficulties. This is achieved by employing advanced data analytics, known as machine learning, to accurately discover the correct dosage level of hydroxyurea that each patient should take. The system can identify when an individual is taking medication, feeling unwell, and moreover when they want to contact their doctor. Essentially, the technology creates a personalised profile of the user for each patient through use of the web-based system.\n
REC name
North West - Liverpool Central Research Ethics Committee
REC reference
17/NW/0184
Date of REC Opinion
25 May 2017
REC opinion
Further Information Favourable Opinion